A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro

Isswariya Anandan; Thulasi Gokul; Neevedha K; Anitha Elango; Priestly Vivekkumar

doi:10.5455/njppp.2023.13.09428202319092023

2024, Vol: 14, Issue: 4

14 / 4Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Online Publishing Date:
03 / 10 / 2023

Natl J Physiol Pharm Pharmacol. 2024; 14(5):

doi: 10.5455/njppp.2023.13.09428202319092023

A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro

Isswariya Anandan, Thulasi Gokul, Neevedha K, Anitha Elango, Priestly Vivekkumar.

Abstract
Background: Breast cancer is notorious for causing mortality and morbidity in most of the cancer patients which is spread to approximately 19.3 million people worldwide. Out of the various drugs available to treat breast cancers, thymoquinone (TMQ) and Paclitaxel (PCT) are known to have significant effects in varied mechanisms. However, only a limited literature is available to prove the activity when given as combined therapy. This opens a new arena for investigations to explore the efficacy of the combined drugs. As a result, a combination of these drugs may be a viable and risk-free treatment option for breast cancer.

Aims and Objectives: The present research was designed to evaluate the individual anti-cancer effects of TMQ and PCT to their combined effects on MCF-7 breast cancer cell lines in an effort to enhance the disease’s therapeutic profile.

Materials and Methods: Breast cancer (MCF-7) cell lines were cultured and incubated after exposure to the drugs in Dulbecco’s modified Eagle’s medium and MTT assay was conducted to determine the cell viability at 540 nm in UV spectroscopy. IC50 individual drugs treated groups TMQ and PCT and combined treatment group (TMQ + PCT) were determined using cell viability graph.

Results: Results showed that the IC50 of TMQ was 31.2 μg/mL, PCT was 57.28 μg/ml, and TMQ + PCT were 4.20 μg/mL which proves the significant activity of the combined drug therapy using combination of TMQ and PCT on MCF-7 cell lines.

Conclusion: This work enables researchers to investigate the potential for synergism between several anticancer medications to establish effective choices for the treatment of breast cancer with a fewer side effects.

Key words: Breast Cancer; MCF-7; Thymoquinone; Paclitaxel; In vitro Anticancer Activity

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Isswariya Anandan Articles by Thulasi Gokul Articles by Neevedha K Articles by Anitha Elango Articles by Priestly Vivekkumar
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Anandan I, Gokul T, K N, Elango A, Vivekkumar P. A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro. Natl J Physiol Pharm Pharmacol. Online First: 03 Oct, 2023. doi:10.5455/njppp.2023.13.09428202319092023

Web Style

Anandan I, Gokul T, K N, Elango A, Vivekkumar P. A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro. https://www.njppp.com/?mno=167976 [Access: March 15, 2024]. doi:10.5455/njppp.2023.13.09428202319092023

AMA (American Medical Association) Style

Anandan I, Gokul T, K N, Elango A, Vivekkumar P. A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro. Natl J Physiol Pharm Pharmacol. Online First: 03 Oct, 2023. doi:10.5455/njppp.2023.13.09428202319092023

Vancouver/ICMJE Style

Anandan I, Gokul T, K N, Elango A, Vivekkumar P. A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro. Natl J Physiol Pharm Pharmacol, [cited March 15, 2024]; Online First: 03 Oct, 2023. doi:10.5455/njppp.2023.13.09428202319092023

Harvard Style

Anandan, I., Gokul, . T., K, . N., Elango, . A. & Vivekkumar, . P. (2024) A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro. Natl J Physiol Pharm Pharmacol, Online First: 03 Oct, 2023. doi:10.5455/njppp.2023.13.09428202319092023

Turabian Style

Anandan, Isswariya, Thulasi Gokul, Neevedha K, Anitha Elango, and Priestly Vivekkumar. 2024. A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro. National Journal of Physiology, Pharmacy and Pharmacology, Online First: 03 Oct, 2023. doi:10.5455/njppp.2023.13.09428202319092023

Chicago Style

Anandan, Isswariya, Thulasi Gokul, Neevedha K, Anitha Elango, and Priestly Vivekkumar. "A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro." National Journal of Physiology, Pharmacy and Pharmacology Online First: 03 Oct, 2023. doi:10.5455/njppp.2023.13.09428202319092023

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Anandan, I., Gokul, . T., K, . N., Elango, . A. & Vivekkumar, . P. (2024) A study on concurring effect of paclitaxel and thymoquinone on MCF-7 cell line – In vitro. National Journal of Physiology, Pharmacy and Pharmacology, Online First: 03 Oct, 2023. doi:10.5455/njppp.2023.13.09428202319092023

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article


About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272